Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
Bladder
Cancer
Coxsackie
Oncolytic
Virus
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
10
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Oncolytic viruses are biological agents which can easily be delivered at high doses directly to the bladder through a catheter (intravesical), with low risk of systemic uptake and toxicity. To date, a number of viruses have been delivered intravesically in patients and in murine models with bladder cancer and antitumour effects demonstrated. Here, we describe in vitro methods to evaluate Coxsackie virus, CVA21, as an oncolytic virus for the treatment of human bladder cancer by determining the susceptibility of bladder cancer cell lines expressing differing levels of ICAM-1 surface receptor to CVA21.
Identifiants
pubmed: 37410244
doi: 10.1007/978-1-0716-3291-8_20
doi:
Substances chimiques
Intercellular Adhesion Molecule-1
126547-89-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-327Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Barocas DA, Globe DR, Colayco DC et al (2012) Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol 8:421709
Svatek RS, Hollenbeck BK, Holmäng S et al (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66(2):253–262
doi: 10.1016/j.eururo.2014.01.006
pubmed: 24472711
Fuge O, Vasdev N, Allchorne P et al (2015) Immunotherapy for bladder cancer. Res Rep Urol 7:65–79
pubmed: 26000263
pmcid: 4427258
Potts KG, Hitt MM, Moore RB (2012) Oncolytic viruses in the treatment of bladder cancer. Adv Urol 2012:404581
doi: 10.1155/2012/404581
pubmed: 22899907
pmcid: 3414001
Goldufsky J, Sivendran S, Harcharik S et al (2013) Oncolytic virus therapy for cancer. Oncolytic Virother 2:31–46
pubmed: 27512656
pmcid: 4918352
Delwar Z, Zhang K, Rennie PS et al (2016) Oncolytic virotherapy for urological cancers. Nat Rev Urol 13(6):334–352
doi: 10.1038/nrurol.2016.84
pubmed: 27215429
Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73
doi: 10.1186/s12916-016-0623-5
pubmed: 27151159
pmcid: 4858828
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
doi: 10.1016/S0092-8674(00)81683-9
pubmed: 10647931
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Choi A, O’Leary M, Fong Y et al (2016) From benchtop to bedside: a review of oncolytic virotherapy. Biomedicine 4(3):18
Bradley S, Jakes AD, Harrington K et al (2014) Applications of coxsackievirus A21 in oncology. Oncolytic Virother 3:47–55
doi: 10.2147/OV.S56322
pubmed: 27512662
pmcid: 4918364
Xiao C, Bator-Kelly CM, Rieder E et al (2005) The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure (Lond Engl 1993) 13(7):1019–1033
doi: 10.1016/j.str.2005.04.011
Shafren DR, Dorahy DJ, Ingham RA et al (1997) Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 71(6):4736–4743
doi: 10.1128/jvi.71.6.4736-4743.1997
pubmed: 9151867
pmcid: 191695
Annels NE, Mansfield D, Arif M et al (2019) Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 25(19):5818–5831
doi: 10.1158/1078-0432.CCR-18-4022
pubmed: 31273010
Pourianfar HR, Javadi A, Grollo L (2012) A colorimetric-based accurate method for the determination of enterovirus 71 titer. Indian J Virol 23(3):303–310
doi: 10.1007/s13337-012-0105-0
pubmed: 24293817
pmcid: 3550799